BRISBANE, Calif., Jan. 7, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that Hoyoung Huh, M.D., Ph.D., BiPar's president and chief executive officer, will present information on BiPar's development programs and product pipeline, including the company's lead product candidate, BSI-201, which is in Phase 2 clinical trials, at the 27th Annual JP Morgan Healthcare Conference in San Francisco, CA.

Dr. Huh will present on Thursday, January 15, 2009, at 12:00 noon PT at the Westin St. Francis Hotel in San Francisco.

About BiPar Sciences and BSI-201

BiPar Sciences, Inc. is a clinical-stage biopharmaceutical company focused on DNA repair using Poly ADP-Ribose Polymerase (PARP) inhibitors. PARP inhibitors represent a new, targeted approach to treating many types of cancers. By preventing cancer cells from repairing their own DNA, PARP inhibitors ultimately cause cancer cell death. The company's lead product candidate is BSI-201, a potential first-in-class and best-in-class PARP inhibitor currently being studied in Phase 2 testing for metastatic triple negative breast cancer, ovarian cancer and other malignancies. The company also has two additional compounds in pre-clinical development, BSI-401, a follow-on PARP inhibitor candidate being investigated as an oral therapy for pancreatic cancer and BSI-302, a novel anti-tubulin therapy. BiPar Sciences is privately held with headquarters in Brisbane, California. For more information, please visit

Continuum Health Communications
Media contact:
Stephanie Ashe